Dosing Begins in Early Trial of Oral Therapy to Protect Dopaminergic Neurons

Dosing Begins in Early Trial of Oral Therapy to Protect Dopaminergic Neurons

287085

Dosing Begins in Early Trial of Oral Therapy to Protect Dopaminergic Neurons

Dosing has begun in a Phase 1 clinical trial testing Inhibikase Therapeutics’ investigational oral therapy IkT-148009 for Parkinson’s disease and related disorders in healthy volunteers. This first clinical trial (NCT04350177) is expected to enroll 112 healthy adults, ages 45 to 70, at a single site in Arizona. More information can be found here.   “The initiation of our Phase 1 study of IkT-148009 for the treatment of Parkinson’s disease represents a significant milestone for Inhibikase,”…

You must be logged in to read/download the full post.